|
|
|
|
GE Healthcares Application for DaTSCAN Ioflupane I123 Injection Accepted by the FDA for Priority Review
- (NewsRx.com) -- GE Healthcare announced that the Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for DaTSCAN (Ioflupane I123 Injection) for priority review.DaTSCAN is a radiopharmaceutical agent containing...
|
|
|
GE Healthcare??s Application for DaTSCAN? Ioflupane I123 Injection Accepted by the FDA for Priority Revi
GE Healthcare announced that the Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for DaTSCAN (Ioflupane I123 Injection) for priority review.DaTSCAN is a radiopharmaceutical agent containing Ioflupane (I) in...
|
|
|
GE Healthcares Application for DaTSCAN (Ioflupane I123 Injection) Accepted by the FDA for Priority R
GE Healthcare announced today that the Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for DaTSCAN (Ioflupane I123 Injection) for priority review.DaTSCAN is a radiopharmaceutical agent containing Ioflupane ...
|
|
|
Medical Minute 6-1: Shutting Down Tremor
Reporter: Melissa Medalie Email Address: news@wctv.tv A | A | A Essential tremor is a condition ten-times more common than Parkinson's.The mind functions fine but the hands, head and neck shake uncontrollably. While she's...
|
|
|
GE Healthcares Application for DaTSCAN (Ioflupane I123 Injection) Accepted by the FDA for Priority Review
- GE Healthcare announced today that the Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for DaTSCAN (Ioflupane I123 Injection) for priority review.DaTSCAN is a radiopharmaceutical agent containing Ioflupane...
|
|
|
GE Healthcare's Application for DaTSCAN (Ioflupane I123 Injection) Accepted by the FDA for Priority Review
A priority review designation is intended for drugs that offer major advances in treatment, or provide treatment where no adequate therapy exists.The FDA's goal is to review and act on 90 percent of NDAs designated as priority review...
|
|
|
GE Healthcare Says FDA Accepts DaTSCAN New Drug Application for Priority Review - Update
PM ET RELATED NEWS TOP MARKET NEWS (RTTNews) - GE Healthcare, a division of General Electric Co.(GE: News ), Tuesday said the Food and Drug Administration or FDA has accepted its New Drug Application or NDA for DaTSCAN - Ioflupane I123...
|
|
|
GE Healthcares Application for DaTSCAN„ (Ioflupane I123 Injection) Accepted by the FDA for Priority
GE Healthcare announced today that the Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for DaTSCAN (Ioflupane I123 Injection) for priority review.DaTSCAN is a radiopharmaceutical agent containing Ioflupane ...
|
|
|
GE Healthcare's Application for DaTSCAN(TM) (Ioflupane I123 Injection) Accepted by the FDA for
BusinessWire - GE Healthcare announced today that the Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for DaTSCAN (Ioflupane I123 Injection) for priority review.DaTSCAN is a radiopharmaceutical agent...
|
|
|
GE Healthcare's Application for DaTSCAN(TM) (Ioflupane I123 Injection) Accepted by the FDA for Priority Review
PRINCETON, N.J.--(BUSINESS WIRE)-- GE Healthcare announced today that the Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for DaTSCAN (Ioflupane I123 Injection) for priority review.DaTSCAN is a...
|
|
|
GE Healthcare's Application for DaTSCAN (Ioflupane I123 Injection) Accepted by the FDA for Priority Review
PRINCETON, N.J.--(BUSINESS WIRE)--GE Healthcare announced today that the Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for DaTSCAN (Ioflupane I123 Injection) for priority review.DaTSCAN is a...
|
|
|
GE Healthcare's Application for DaTSCAN(TM) (Ioflupane I123 Injection) Accepted by the FDA for Priority Review
PRINCETON, N.J.--(BUSINESS WIRE)-- GE Healthcare announced today that the Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for DaTSCAN (Ioflupane I123 Injection) for priority review.DaTSCAN is a...
|
|
|
GE HealthcareEURs Application for DaTSCAN (Ioflupane I123 Injection) Accepted by the FDA for Priority Revi
Company Website: http:www.gehealthcare.com PRINCETON, N.J.-- (Business Wire) GE Healthcare announced today that the Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for DaTSCAN (Ioflupane I123 Injection) for...
|
|
|
GE Healthcare's Application for DaTSCAN (Ioflupane I123 Injection) Accepted by the FDA for Priority Review
PRINCETON, N.J.--(BUSINESS WIRE)--GE Healthcare announced today that the Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for DaTSCAN (Ioflupane I123 Injection) for priority review.DaTSCAN is a...
|
|
|
GE Healthcare's Application for DaTSCAN(TM) (Ioflupane I123 Injection) Accepted by the FDA for Priority Review
GE Healthcare announced today that the Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for DaTSCAN (Ioflupane I123 Injection) for priority review.DaTSCAN is a radiopharmaceutical agent containing Ioflupane ...
|
|
|
GE Healthcare's Application for DaTSCAN (Ioflupane I123 Injection) Accepted by the FDA for Priority Review
PRINCETON, N.J.- (BUSINESS WIRE) - GE Healthcare announced today that the Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for DaTSCAN (Ioflupane I123 Injection) for priority review. DaTSCAN is a...
|
|
|
GE HealthcareEURs Application for DaTSCAN„ (Ioflupane I123 Injection) Accepted by the FDA for Priori
A priority review designation is intended for drugs that offer major advances in treatment, or provide treatment where no adequate therapy exists.The FDA's goal is to review and act on 90 percent of NDAs designated as priority review...
|
|
|
Workshop Develops Research Roadmap For Focused Ultrasound Treatment Of Brain Disorders
The primary objective of this workshop was to develop a comprehensive R&D roadmap that would fast-track the use of focused ultrasound technology to treat a variety of brain disorders including benign and malignant tumors, Parkinson...
|
|
|
Alseres & US FDA reach SPA agreement for phase-III trial of Altropane
Alseres Pharmaceuticals, Inc has reached agreement with the US Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for the phase-III protocol of Alseres' Altropane Molecular Imaging Agent to aid in the...
|
